Kinetolab

Slide 1
NEW COMPOUNDS
GIVE A NEW HOPE

KINETO Lab’s expert team manages the whole process of drug development from target identification and validation through high throughput in vitro screenings to in vivo animal models studies

Slide 2
SERVICES
IN VITRO – IN VIVO – EX VIVO

Our mission is to enhance the quality of drug discovery and developmental concept of our partners by providing high quality services on various tumor models which allow you to design the most suitable study to prove a concept of your research, in order to reach the clinical stage faster

Slide 3
PDTX

Patient-derived tumor xenografts (PDTX) as clinically relevant models reflect tumor microenvironment of the patients, improving the reliability of translational research and predictability of clinical therapeutic response

15 years experienced cancer research biotech

We are a biotechnological research and CRO company which aims to use scientifically founded strategies to identify and validate new drug targets and use preclinical models for testing and developing mainly new anticancer and other anti-disease technologies and treatments.

Our company can fast, cost-effective and accurate prove a developmental concept of your research.

about us

KINETO Lab has extensive expertise and substantial experience in designing experiments to be used along the preclinical drug discovery pipeline for successful and effective research and development of anticancer drugs

research& development

DRUG DEVELOPMENT

Given the still dismal overall prognosis for cancer patients, the need is evident to discover and develop novel targeted and personalized anticancer therapies, where we are contributing in numerous self- and grant- funded projects

read more

PDTX MODELS

We successfully developed our system to establish, maintain and archive PDTX models in order to provide numerous options to our partners to use the most reliable preclinical models for in vivo drug testing

read more

TARGET IDENTIFICATION

KINETO Lab is discovering novel molecular targets of tumor cells, leading to effective therapeutics development. New homing domains can selectively deliver the drugsh to its site of action

read more

ANTIBODY DEVELOPMENT

KINETO Lab intends to expand its existing tissue culture and animal- based infrastructure on the way that it can continually be able to isolate larger amount of antibodies

read more

DIAGNOSTICS

We are developing detection methods and devices by which it is possible to detect and capture a specific cell type using combined markers in order to improve cancer diagnosis and prognosis

read more

PARTNERSHIP

KINETO Lab was participating in several successful projects in consortiums with industrial and academic institutions during the past years.
We believe in a collaborative model, based on strong partnerships, enabling us to share and provide our technologies and knowledge, enhancing the quality of research and developmental concept of our partners.

ARE YOU WILLING TO HAVE A TRUSTFUL PARTNER AND MAKE SUCCESSFUL COLLABORATION?

If you would like to become our partner, please contact us.

SERVICES

All the NEW COMPOUNDS successfully tested in preclinical phase GIVE NEW HOPE for better anticancer treatment.

KINETO Lab is an acknowledged expert providing tailored and unique methods to identify and validate new drug targets and to evaluate in vitro and in vivo activity of anticancer drugs in the preclinical drug discovery.

IN VITRO

KINETO Lab offers and provides wide range of in vitro preclinical services on various tumor models which allow you to determine the activity of your compound, select the best compound and develop your therapeutics

EX VIVO

We provide tumor and organ samples, which can be routinely processed, characterized and evaluated with validated pathological, biochemical and histological analysis methods supporting your research

IN VIVO

Demonstrating the antitumor activity of a novel agent in animal models is important step in preclinical drug development, therefore we propose in vivo preclinical models which can be used per se or associated with imaging modalities to permit the evaluation of the efficacy of newly developed therapeutics

immuno-oncology

In order to study immunology aspects of cancer KINETO Lab provides in vitro and in vivo models suitable to prove your developmental concept

CONSULTANCY

Nowadays, polyhistorians in the classical sense no longer work effectively. Good quality scientific work requires cooperation between representatives of different disciplines.

We can provide you with assessment,
advice and ideas on biological issues

If you are a chemistry-related research laboratory involved in drug development, and if you are planning a new project, or already have ongoing projects where the biological aspects of the topic and feasibility and rationality arise, we can provide you with assessment, advice and ideas on biological issues to put your research on the scientific or business map.

CONSULTANCY

Nowadays, polyhistorians in the classical sense no longer work effectively. Good quality scientific work requires cooperation between representatives of different disciplines.

We can provide you with assessment,
advice and ideas on biological issues

If you are a chemistry-related research laboratory involved in drug development, and if you are planning a new project, or already have ongoing projects where the biological aspects of the topic and feasibility and rationality arise, we can provide you with assessment, advice and ideas on biological issues to put your research on the scientific or business map.

PRODUCTS

KINETO Lab produces an anti-human CD34 monoclonal antibody.

Additionally, we offer different samples from in vitro and in vivo experiments, for your further analyses.

ANTIBODY
KINETO Lab has the technology to produce anti-human CD34 monoclonal antibody, by immunizing BALB/c mice with purified recombinant extracellular domain of human CD34 protein, which binds for different types of stem cells and progenitor cells, as well as vascular endothelial cells and embryonic fibroblasts.
BIOLOGICAL SAMPLES

We can prepare and ship different samples from in vitro and in vivo experiments, for your further analyses.

Additionally, we can perform the molecular biology analysis service in our lab, providing you final results.

NEWS

16/04/2024

The study about potential clinical benefits of combining KRAS-G12C inhibitors with farnesyltransferase inhibitors was presented at AACR Annual Meeting

At AACR Annual Meeting which held in San Diego Convention Center, San Diego, California, USA, from April 5th to 10th, 2024, our chief scientific officer Dr. József Tóvári presented the poster with the title „Antitumor effects of KRAS-G12C inhibitors can be improved by farnesyltransferase inhibitors in preclinical models”.

07/03/2024

Published a study about a gluing docking method for finding small molecules that bind to both the GAP and the mutated KRAS molecules

read more

10/02/2023

Published a new study on targeting KRAS with combination of KRAS-G12C and Farnesyl-transferase inhibitors in British Journal of Cancer

read more

05/01/2024

Attending NEXGEN-PD consortium meeting on January 11th to 12th, 2024 in Salzburg, Austria

read more

CONTACTS

If you have any question regarding our research, services or PDTX models, and if you want to get in touch with us, fill the form or send us an e-mail on info@kinetolab.hu.

We are always open for your CV and application in case you would like to work in an innovative, dynamically growing cancer research-related biotech company in the future. If you think you could fit in KINETO Lab’s team, please contact us.